Jane Ryan
Independent Non-Executive DirectorDr. Jane Ryan, Ph.D., MAICD, B.Sc. (Hons), served as the Chief Operating Officer of BCAL Diagnostics Limited until September 21, 2023. She has served as a commercial and product development advisor to BCAL Diagnostics since March 2021. Dr. Ryan serves as Independent Non-Executive Director at Neuphoria Therapeutics Inc. (formerly known as Bionomics Limited) since October 1, 2020. She served as Independent Non-Executive Director at Anatara Lifesciences Limited from September 01, 2018 until October 2, 2023. Since January 2014, Dr. Ryan has provided executive-level advisory services to biotechnology companies in connection with capital raising, business development and mergers and acquisitions. Dr. Ryan has been an Independent Non-Executive Director of IDT Australia Limited since January 28, 2022. She served as Vice President of Product Development & Strategic Marketing at Biota Holdings Ltd. and as Vice President of Product Development for Biota Holdings Ltd. She served as Director at the Victorian Endowment for Science Knowledge and Innovation (veski), Diabetes Victoria, TechInSA and the Diabetes Vaccine Development Centre. She has international experience in the pharmaceutical and biotechnology industries, where she has held executive roles in the management of research and development programs as well as business development and alliance management. She served as Director of Business Development at Biota Holdings Ltd., where her responsibilities included managing Biota’s alliance with Thermo Electron and overseeing preclinical and clinical development plans for Biota’s research programs. She serves as a Director at Bio Innovation SA. Dr. Ryan has worked in Australia, the United States, the United Kingdom and internationally with companies including Peptech, Roche and Cambridge Antibody Technology. She currently serves as a non-executive director of Viral Vector Manufacturing Facility Pty Ltd. Dr. Ryan serves as chair of the Advisory Board at the ithree Institute at the University of Technology Sydney. Throughout her career, she has led many successful fundraising campaigns and licensing initiatives, including the awarding of a US Government contract. From 2014 to 2017, Dr. Ryan served as the CEO of Sementis Ltd., a public company (unlisted) developing vaccine technology. She is also a member of the Australian Institute of Company Directors. She received her B.Sc. from the Australian National University, her Ph.D. from Macquarie University and was a Postdoctoral Fellow at Columbia University.
Positions
- Company NameNeuphoria Therapeutics Inc.Stock CodeNEUPPositionIndependent Non-Executive DirectorColleagues
- SPSpyridon PapapetropoulosInterim CEO & Executive Director
- ADAlan David FisherIndependent Non-Executive Chair of the Board
- TMTimothy M. CunninghamFractional CFO
- JKJulie KernerSenior Vice President of Business Operations
- AHAdrian HintonFinancial Controller
- RCRajeev ChandraCompany Secretary
- DIDavid Ian WilsonIndependent Non-Executive Director
- MBMurray B. SteinMember of Clinical Advisory Board
